BioMarin Pharmaceutical reported first-quarter revenues of $766.2 million, up 2.8% year on year but falling short of analysts' expectations by 1.3%. The company achieved the highest full-year guidance raise among the 11 therapeutics stocks tracked, though it also posted a significant miss of analysts' EPS estimates. Moderna delivered the fastest revenue growth in the group, with revenues of $389 million surging 260% year on year and beating estimates by 55.8%. United Therapeutics was the weakest performer, with revenues of $781.5 million down 1.6% year on year and missing estimates by 1.9%. Overall, the therapeutics group beat consensus revenue estimates by 14.5% on average, and share prices have risen 7.6% on average since the latest earnings results.
Biomarin Pharmaceutical IncQ1 revenue missed estimates by 1.3% and EPS missed significantly.
Moderna IncRevenue surged 260% YoY and beat estimates by 55.8%.
United Therapeutics CorporationRevenue fell 1.6% YoY and missed estimates by 1.9%.
Biogen Inc
Gilead Sciences Inc